MedDataX Logo

Open-Label Extension of Other SZ1839 (Iressa) Trials

NCT ID: NCT00635973

Last Updated: 2009-04-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-02-29

Study Completion Date

2003-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A trial to assess patients who have been treated with Iressa in a previous clinical trial and may benefit from continued treatment with Iressa.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study in Healthy Men to Test How Itraconazole Influences the Amount of Zongertinib (BI 1810631) in the Blood

NCT05833139

Healthy
COMPLETED PHASE1

Effects of Ezetimibe With Simvastatin in the Therapy of Adolescents With HeFH (Study P02579)

NCT00129402

Hypercholesterolemia
COMPLETED PHASE3

A Study of the Effect of Efavirenz on the Plasma Levels of Nemtabrutinib (MK-1026-014)

NCT06698016

Healthy
COMPLETED PHASE1

Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019)

NCT03885921

Hypercholesterolemia
COMPLETED PHASE3

Eze/Simva Switch Study in Diabetics (0653A-807)

NCT00541697

Diabetes Mellitus, Type 2
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Gefitinib (Iressa)

Iressa

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Received treatment in a previous Iressa clinical trial
* Provided Informed Consent to participate in the trial
* 30 days or less since completing the previous Iressa trial.

Exclusion Criteria

* Radiotherapy completed more than 14 days before starting treatment in this trial
* Incomplete healing from prior surgery
* Withdrawal from previous Iressa trial due to unacceptable toxicity to major organs
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D7913C00026

Identifier Type: -

Identifier Source: secondary_id

1839IL/0026

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Retosiban (GSK221149) When Dosed With Efavirenz (EFZ)
NCT01867996 COMPLETED PHASE1
Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)
NCT03867318 COMPLETED PHASE3
A Study to Evaluate Drug-Drug Interactions of Obicetrapib Tablets and Ezetimibe Tablets in Healthy Adult Subjects
NCT06547359 COMPLETED PHASE1
A Trial of DDI Between SHR1459 and Efavirenz With Healthy Subjects
NCT05560360 COMPLETED PHASE1
Effect of Ezetimibe Treatment on Low-density Lipoprotein Cholesterol (LDL-C) Levels in Participants With Coronary Heart Disease (CHD) Already Treated With a Statin (MK-0653A-205 AM1)
NCT01381679 COMPLETED
Bioavailability and Bioequivalence of Ezetimibe Tablets in Healthy Subjects
NCT05681247 COMPLETED PHASE1
Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment
NCT00162097 COMPLETED PHASE1
Intensive Pharmacokinetics of the Nelfinavir-Rifabutin Interaction in Patients With HIV-Related Tuberculosis Treated With a Rifabutin-Based Regimen
NCT00018083 UNKNOWN NA
GSK1349572 Drug Interaction Study With Efavirenz
NCT01098526 COMPLETED PHASE1
Ezetrol Post-Marketing Study
NCT00753883 COMPLETED PHASE4
TWICE (Ezetimibe Together With Any Statin Cholesterol Enhancement)(0653-060)
NCT00328523 COMPLETED PHASE3
Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol Targets
NCT00908011 COMPLETED NA
Pharmacokinetic and Pharmacodynamic Interactions Between the Cholesterol-lowering Ezetimibe and the Non-nucleoside Reverse Transcriptase Inhibitor Efavirenz During Chronic Treatment in Healthy Volunteers With Reference to Intestinal Expression of CYP3A4, UGT1A1, ABCB1 and ABCC2
NCT00810303 COMPLETED PHASE1
Regeneron 1331 Kinetics Sub-Study HoFH
NCT04722068 COMPLETED NA
The Effect of Gemfibrozil, Ketoconazole and Clarithromycin on the Amount of LY2409021 in the Bloodstream
NCT01836198 COMPLETED PHASE1
A Research Study to Evaluate MK0653 (Ezetimibe) and Simvastatin, Given Together and Alone, on Intestinal Absorption of Cholesterol (0653-050)(COMPLETED)
NCT00652301 COMPLETED PHASE3
Pharmacokinetic Drug Interaction Between Ezetimibe and Sirolimus After Single Dose Administration in Healthy Subjects
NCT00621101 COMPLETED PHASE1
Effect of Repeated Administration of Eslicarbazepine Acetate on the Pharmacokinetics of Simvastatin in Healthy Subjects
NCT00987558 COMPLETED PHASE1
A Study of the Effect of a Moderate CYP3A Inducer Efavirenz on Quizartinib Pharmacokinetics in Healthy Participants
NCT04459598 COMPLETED PHASE1
A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men
NCT02138799 COMPLETED PHASE1
Doravirine Versus Integrase Inhibitors on Backbone of Emtricitabine and Tenofovir Alafenamide in HIV
NCT04820933 COMPLETED EARLY_PHASE1
MD Ezetimibe Cyclosporine Interaction (0653-057)
NCT00653276 COMPLETED PHASE1
The PostprAndial eNdothelial Function After Combination of Ezetimibe and simvAstatin Study
NCT00817843 COMPLETED PHASE4
Drug-Drug Interaction of Pyrotinib With a Moderate CYP3A Inducer
NCT04680091 UNKNOWN PHASE1
Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults
NCT00099684 COMPLETED NA